Fortnightly review: Drug treatment of depression

Spigset, Olav; Mårtensson, Björn

doi:10.1136/bmj.318.7192.1188

Cited by 44 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is widely accepted that approximately 40% of patients will respond partially to the antidepressant or will not respond at all (Guscott and Grof, 1991;Spigset and Martensson, 1999;Quitkin et al, 2000). In our study, as expected, 30% of the patients did not reach remission at the end of week 12, which means that they do not correctly respond to citalopram.…”

Section: Discussioncontrasting

confidence: 61%

Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

et al. 2005

View full text Add to dashboard Cite

In the context of a long-term follow-up study, we analysed the possible implication of the 5-HT(1A) receptor gene (HTR1A) -1018C/G polymorphism in the clinical outcome of major depressive patients treated with citalopram. We had previously reported an association between variation on the SERT gene (SLC6A4) and clinical remission after citalopram treatment. In the present 12-week follow-up study, the combined effect of HTR1A and SLC6A4 genes in clinical outcome and response to citalopram was also evaluated. The sample consisted of 130 patients, all of Spanish origin, who were diagnosed as having a current major depressive episode according to DSM-IV criteria. A 21-item Hamilton Depression Rating Scale was used to assess severity of symptoms at the beginning and during the follow-up to determine the outcome and remission status at week 12. Patients were genotyped for HTR1A gene and, in addition, for two polymorphisms at the CYP2C19 gene, which together account for the 87% of the Caucasian poor metabolizer phenotype. Data were analysed adjusting for the effect of poor metabolizers in clinical response. No independent effect was found for the 5-HT(1A) receptor gene in relation to clinical outcome or remission after citalopram treatment. However, a combined genetic effect of HTR1A and SLC6A4 genes was found to influence the clinical outcome of patients [F(4,102) = 2.89, p= 0.02]. When considering the remission status, an increase of patients carrying the risk genotype combination (S/S-G/G) was found among those subjects who did not reach remission (Fisher's exact test = 0.009). Our results suggest that the combined effect of the serotonin transporter and the 5-HT(1A) receptor genes could be related to the clinical outcome of depressive patients treated with citalopram.

show abstract

Section: Discussioncontrasting

confidence: 61%

Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Probably trazodone, amitriptyline and other TCAs are prescribed on account of their sedative properties, which make them appropriate for elderly people suering from a wide range of psychological problems. SSRIs and newer ADs can cause a range of activating side eects, including tremor, nervousness, akathisia and insomnia, making them less attractive in late life [19,20]. Another problem with ADs relates to discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database

Pietraru¹,

Barbui

Poggio³

et al. 2001

European Journal of Clinical Pharmacology

View full text Add to dashboard Cite

In Italy, databases have been used to monitor the prescription of medicines, but they have always provided aggregate data on drug sales and consumption. In this study, a sample of typical patients receiving antidepressants under real-world conditions was analysed to help clarify what happens in clinical practice. Databases of patients receiving antidepressants should be adopted to suggest public health priorities and generate original research hypotheses to be formally tested with experimental studies.

show abstract

“…Establishing the optimum dose of an antidepressant is a problem in practice (Spigset and Martensson 1999), as well as in clinical trials (Benkert et al 1996), because many of the possible disturbing side-effects of TCAs occur at sub-therapeutic doses. Flexible dosing, as used in previous studies, leads to the risk of under-dosing of the TCA (Bollini et al 1999).…”

Section: Discussionmentioning

confidence: 99%

A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients

et al. 2004

View full text Add to dashboard Cite

show abstract

Fortnightly review: Drug treatment of depression

Cited by 44 publications

References 23 publications

Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database

A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients

Contact Info

Product

Resources

About